| Autor: |
Blau, Kristin, Lehr, Sophia, Aschoff, Roland, Al Gburi, Suzan, Brück, Normi, Chapsa, Maria, Schnabel, Anja, Abraham, Susanne, Jöhrens, Korinna, Beissert, Stefan, Günther, Claudia |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2023, Vol. 37 Issue 1, pe29-e31, 3p |
| Abstrakt: |
This correlated with a lower incidence of chilblain-like lesions and might explain the observed decrease in chilblain-like lesions since winter 2022. Dear Editor, Exposure to Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) with mild COVID-19 disease can be followed by post-COVID cutaneous inflammation with a spectrum ranging from vasculitis to acral chilblain lesions.[[1], [3]] We have shown that chilblain-like lesions are characterized by activation of the type I interferon (IFN) pathway indicated by expression of human myxovirus resistance protein 1 (MXA) and phosphorylated Janus kinase 1 (JAK1) in lesional skin.[5] To further understand the clinical course and pathogenesis of SARS-CoV-2 associated chilblain-like lesions we followed 25 patients presenting to our department with new chilblain lesions during 2 years of the pandemic (2020-2022; Figure 1a). Symptoms ranged from mild reddish pale infiltrated to severe bullous, sporadically necrotic skin lesions at feet (17 patients) and hands (five patients) or both (three patients; Figure 2a). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text